Tag Archives: Brenntag and ArcticZymes Join Forces to Support Growth in Biopharmaceutical and Gene Therapy Markets

New Distribution Agreement Between Brenntag and ArcticZymes Strengthens European Access to Advanced Enzymes for Biopharma Production

(IN BRIEF) Brenntag has signed an exclusive European distribution agreement with ArcticZymes AS for its line of salt-active nucleases—SAN HQ, SAN-HQ GMP, M-SAN HQ, and M-SAN HQ GMP—used in gene therapy, vaccine manufacturing, and bioprocessing. Signed during the CPHI fair … Read the full press release